Cargando…

Metabolomics: A Tool to Understand the Impact of Genetic Mutations in Amyotrophic Lateral Sclerosis

Metabolomics studies performed in patients with amyotrophic lateral sclerosis (ALS) reveal a set of distinct metabolites that can shed light on the pathological alterations taking place in each individual. Metabolites levels are influenced by disease status, and genetics play an important role both...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lanznaster, Débora, Veyrat-Durebex, Charlotte, Vourc’h, Patrick, Andres, Christian R., Blasco, Hélène, Corcia, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288444/ https://www.ncbi.nlm.nih.gov/pubmed/32403313 http://dx.doi.org/10.3390/genes11050537

Ejemplares similares

Study of Ubiquitin Pathway Genes in a French Population with Amyotrophic Lateral Sclerosis: Focus on HECW1 Encoding the E3 Ligase NEDL1
por: Haouari, Shanez, et al.
Publicado: (2023)

Implication of Central Nervous System Barrier Impairment in Amyotrophic Lateral Sclerosis: Gender-Related Difference in Patients
por: Alarcan, Hugo, et al.
Publicado: (2023)

Some CSF Kynurenine Pathway Intermediates Associated with Disease Evolution in Amyotrophic Lateral Sclerosis
por: Alarcan, Hugo, et al.
Publicado: (2021)

The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?
por: Hergesheimer, Rudolf C, et al.
Publicado: (2019)

Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis
por: Lanznaster, Débora, et al.
Publicado: (2020)

The Roles of NEDD4 Subfamily of HECT E3 Ubiquitin Ligases in Neurodevelopment and Neurodegeneration
por: Haouari, Shanez, et al.
Publicado: (2022)

Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?
por: Alarcan, Hugo, et al.
Publicado: (2022)

TDP-43-Mediated Toxicity in HEK293T Cells: A Fast and Reproducible Protocol To Be Employed in the Search of New Therapeutic Options against Amyotrophic Lateral Sclerosis
por: Lanznaster, Débora, et al.
Publicado: (2019)

Is There a Role for Vitamin D in Amyotrophic Lateral Sclerosis? A Systematic Review and Meta-Analysis
por: Lanznaster, Débora, et al.
Publicado: (2020)

Metabolic Profile and Pathological Alterations in the Muscle of Patients with Early-Stage Amyotrophic Lateral Sclerosis
por: Lanznaster, Débora, et al.
Publicado: (2022)

(1)H-NMR-Based Metabolomic Profiling of CSF in Early Amyotrophic Lateral Sclerosis
por: Blasco, Hélène, et al.
Publicado: (2010)

Conditioned Medium from Cells Overexpressing TDP-43 Alters the Metabolome of Recipient Cells
por: Hergesheimer, Rudolf, et al.
Publicado: (2020)

Correction: (1)H-NMR-Based Metabolomic Profiling of CSF in Early Amyotrophic Lateral Sclerosis
por: Blasco, Hélène, et al.
Publicado: (2010)

Dysregulations of Expression of Genes of the Ubiquitin/SUMO Pathways in an In Vitro Model of Amyotrophic Lateral Sclerosis Combining Oxidative Stress and SOD1 Gene Mutation
por: Dangoumau, Audrey, et al.
Publicado: (2021)

A ferroptosis–based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis
por: Devos, David, et al.
Publicado: (2019)

Author Correction: A ferroptosis–based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis
por: Devos, David, et al.
Publicado: (2020)

Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS
por: Lanznaster, Débora, et al.
Publicado: (2018)

How Can a Ketogenic Diet Improve Motor Function?
por: Veyrat-Durebex, Charlotte, et al.
Publicado: (2018)

Iron Metabolism Disturbance in a French Cohort of ALS Patients
por: Veyrat-Durebex, Charlotte, et al.
Publicado: (2014)

Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?
por: Moreau, Caroline, et al.
Publicado: (2018)

The Relevancy of Data Regarding the Metabolism of Iron to Our Understanding of Deregulated Mechanisms in ALS; Hypotheses and Pitfalls
por: Petillon, Camille, et al.
Publicado: (2019)

Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS
por: Blasco, H., et al.
Publicado: (2017)

Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole
por: Corcia, Philippe, et al.
Publicado: (2012)

Current view and perspectives in amyotrophic lateral sclerosis
por: Mathis, Stéphane, et al.
Publicado: (2017)

Inhibition of β-Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis
por: Henriques, Alexandre, et al.
Publicado: (2017)

Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases
por: Lanznaster, Débora, et al.
Publicado: (2022)

Genetic variability in sporadic amyotrophic lateral sclerosis
por: Van Daele, Sien Hilde, et al.
Publicado: (2023)

Blood Cell Palmitoleate-Palmitate Ratio Is an Independent Prognostic Factor for Amyotrophic Lateral Sclerosis
por: Henriques, Alexandre, et al.
Publicado: (2015)

Elevated Serum Ferritin Is Associated with Reduced Survival in Amyotrophic Lateral Sclerosis
por: Nadjar, Yann, et al.
Publicado: (2012)

Molecular Imaging of Microglial Activation in Amyotrophic Lateral Sclerosis
por: Corcia, Philippe, et al.
Publicado: (2012)

Sex-dependent effects of chromogranin B P413L allelic variant as disease modifier in amyotrophic lateral sclerosis
por: Ohta, Yasuyuki, et al.
Publicado: (2016)

Amyotrophic Lateral Sclerosis and Metabolomics: Clinical Implication and Therapeutic Approach
por: Kumar, Alok, et al.
Publicado: (2013)

The longitudinal cerebrospinal fluid metabolomic profile of amyotrophic lateral sclerosis
por: Gray, Elizabeth, et al.
Publicado: (2015)

TDP-43—The key to understanding amyotrophic lateral sclerosis
por: Xu, Zuoshang, et al.
Publicado: (2014)

Prionoids in amyotrophic lateral sclerosis
por: Gosset, Philippe, et al.
Publicado: (2022)

Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosis
por: Naumann, Marcel, et al.
Publicado: (2019)

Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol
por: Albanese, Alberto, et al.
Publicado: (2022)

Amyotrophic lateral sclerosis
por: Wijesekera, Lokesh C, et al.
Publicado: (2009)

Evidence of Social Understanding Impairment in Patients with Amyotrophic Lateral Sclerosis
por: Cavallo, Marco, et al.
Publicado: (2011)

Recent advances in understanding amyotrophic lateral sclerosis and emerging therapies
por: Gittings, Lauren M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r13pf602j4iqaq3m1eq2k86fe8